Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
While escaping cancer is usually a huge relief, it can at the same time leave the patient with "ongoing pain," according to the American Cancer Society. But that pain can be reduced if a survivor remains physically active or returns to being so, the researchers found, after investigating information covering over 60,000 adults, around 10,000 of whom had a cancer diagnosis. The participants were asked to evaluate any pain they felt, on a 0-10 scale, and were then asked about how physically active
Ensysce Biosciences Inc (NASDAQ:ENSC) received an FDA Breakthrough Therapy Designation (BTD) for PF614-MPAR, a next-generation opioid. BTD has been granted to fewer than 300 drugs. It is designed to expedite the development and reviewing of drugs intended to treat a serious condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies. PF614-MPAR is designed to provide optimal pain relief at prescribed doses yet limit accid
Vertex Pharmaceuticals said on Wednesday its drug, VX-548, was successful in reducing nerve pain in patients in a mid-stage trial. Treatment with the drug resulted in a statistically significant reduction in weekly average of daily pain intensity, as measured on a scale at 12 weeks. The trial studied the non-opioid pain drug in patients with diabetic peripheral neuropathy, a type of nerve damage caused by high blood sugar.